Score breakdown
Expansionlocations & platform
6
Capitalfunding, M&A, IPO
5
Pricing powerraising vs discounting
7
Talenthires & leadership
3
Why it moved
Dropped a clinical-grade genome to $599 ("Genomics for All"), commoditizing the longevity entry point. A real move, but near-zero search demand keeps it low.
What would move it next quarter
The $599 genome converting into real search and volume, or a distribution partner (a gym or longevity chain) that supplies the demand it lacks.